Overview
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor exon 19 deletions or exon 21 (L858R) point mutations. It is also indicated in combination with docetaxel for the treatment of metastatic non-small cell lung cancer in patients who have progressed following prior platinum-based chemotherapy. Patients who have EGFR or ALK genomic aberrations should also have disease progression following FDA-approved therapy for these aberrations. Ramucirumab, in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan), is indicated for the treatment of metastatic colorectal cancer in patients who have progressed following therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Lastly, ramucirumab is indicated for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level ≥400 ng/mL and have previously been treated with sorafenib.
Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Metastatic Colorectal Cancer (CRC)
- Metastatic Non-Small Cell Lung Cancer
- Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Research Report
A Comprehensive Monograph on Ramucirumab (Cyramza): Pharmacology, Clinical Efficacy, and Therapeutic Role in Oncology
Section 1: Executive Summary & Drug Profile
1.1. Overview
Ramucirumab, marketed under the brand name Cyramza®, is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that functions as a direct and specific antagonist of Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2).[1] By selectively targeting this key receptor, ramucirumab inhibits tumor angiogenesis—the formation of new blood vessels that are essential for tumor growth, survival, and metastasis.[4] This mechanism of action has established ramucirumab as an important therapeutic agent in the treatment of several advanced or metastatic solid tumors. It has secured regulatory approvals for use in gastric and gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), and a biomarker-defined subpopulation of hepatocellular carcinoma (HCC).[2]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/08/01 | Not Applicable | Not yet recruiting | |||
2025/05/30 | Phase 1 | Recruiting | |||
2025/01/13 | Phase 1 | Recruiting | FBD Biologics Limited | ||
2024/11/08 | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | ||
2024/11/05 | Phase 1 | Recruiting | City of Hope Medical Center | ||
2024/09/27 | Phase 2 | Recruiting | |||
2024/08/21 | Phase 2 | Not yet recruiting | |||
2024/08/07 | Phase 1 | Active, not recruiting | |||
2024/06/07 | Phase 2 | Recruiting | |||
2024/06/06 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Eli Lilly and Company | 0002-7669 | INTRAVENOUS | 10 mg in 1 mL | 5/29/2019 | |
| Eli Lilly and Company | 0002-7678 | INTRAVENOUS | 10 mg in 1 mL | 5/29/2019 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 12/19/2014 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML | SIN15035P | INJECTION, SOLUTION, CONCENTRATE | 10mg/ml | 6/21/2016 | |
| CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML | SIN15036P | INJECTION, SOLUTION, CONCENTRATE | 10mg/ml | 6/21/2016 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| CYRAMZA ramucirumab 500 mg/50 mL solution for intravenous infusion vial | 227352 | Medicine | A | 7/23/2015 | |
| CYRAMZA ramucirumab 100 mg/10 mL solution for intravenous infusion vial | 227351 | Medicine | A | 7/23/2015 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| CYRAMZA | eli lilly canada inc | 02443805 | Solution - Intravenous | 10 MG / ML | 9/10/2015 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| CYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION | 114957001 | CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized | |
| CYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION | 114957003 | CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized | |
| CYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION | 114957001IP | CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized | |
| CYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION | 114957003IP | CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.